Matrine (Synonyms: NSC 146051, NSC 318810) |
Katalog-Nr.GC17874
One-Click Copy Product Info
|
Matrine is an alkaloid found in Sophora japonica plants that acts as a kappa opioid receptor and µ-receptor agonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 519-02-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Matrine is an alkaloid found in Sophora japonica plants that acts as a kappa opioid receptor and µ-receptor agonist[1]. Matrine has multiple pharmacological effects, including anticancer, anti-oxidative stress, anti-inflammatory and anti-apoptotic effects[2].
In vitro, treatment of A549, DU145 and MIA PaCa-2 cells with Matrine (50 μM) for 24 h inhibited the expression of CXC chemokine receptor type 4 (CXCR4), downregulated the levels of matrix metalloproteinases (MMP-2 and MMP-9), and weakened cell migration activity[3]. Matrine (50-500 μg/ml) treated gastric cancer cell line MNK45 inhibited cell proliferation in a dose-dependent manner with an IC50 value of 540 μg/ml, and significantly affected the expression of intracellular NF-κB, XIAP, CIAP and p-ERK proteins[4]. Matrine (0.5-2.0 mg/mL) treated D341 cells for 24-72h induced apoptosis in a dose-dependent manner and increased the expression of apoptosis-related genes such as Bax, caspase-3, and caspase-9 [5].
In vivo, Matrine (300mg/kg) was orally administered to diabetic cardiomyopathy (DbCM) rats for 10 days, which reduced left ventricular function damage, restored cardiac compliance loss, and inhibited cardiac fibrosis caused by activation of the TGF-β1/Smad signaling pathway[6]. Matrine (150, 25mg/kg) was intraperitoneally injected to treat experimental autoimmune encephalomyelitis (EAE) rats, which reduced the clinical severity of EAE, reduced central nervous system cell infiltration, protected type IV collagen and ZO-1 mRNA expression, and regulated the balance between MMP-9 and tissue inhibitor of metalloproteinases (TIMP-1) in serum[7].
References:
[1] Alamgir A N M, Alamgir A N M. Secondary metabolites: Secondary metabolic products consisting of C and H; C, H, and O; N, S, and P elements; and O/N heterocycles[J]. Therapeutic use of medicinal plants and their extracts: volume 2: phytochemistry and bioactive compounds, 2018: 165-309.
[2] Chen X, Liu P, Mao Y, et al. Research Advancements in Pharmacological Activities and Mechanisms of Matrine[J]. Pharmacognosy Magazine, 2024, 20(1): 189-205.
[3] Jung Y Y, Um J Y, Narula A S, et al. Identification of matrine as a novel regulator of the CXCR4 signaling axis in tumor cells[J]. International Journal of Molecular Sciences, 2020, 21(13): 4731.
[4] Luo C, Zhong H J, Zhu L M, et al. Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism[J]. Molecular Biology Reports, 2012, 39: 5459-5464.
[5] Zhou K, Ji H, Mao T, et al. Effects of matrine on the proliferation and apoptosis of human medulloblastoma cell line D341[J]. International journal of clinical and experimental medicine, 2014, 7(4): 911.
[6] Zhang Y, Cui L, Guan G, et al. Matrine suppresses cardiac fibrosis by inhibiting the TGF‑β/Smad pathway in experimental diabetic cardiomyopathy[J]. Molecular Medicine Reports, 2018, 17(1): 1775-1781.
[7] Zhang S, Kan Q C, Xu Y, et al. Inhibitory Effect of Matrine on Blood‐Brain Barrier Disruption for the Treatment of Experimental Autoimmune Encephalomyelitis[J]. Mediators of Inflammation, 2013, 2013(1): 736085.
| Cell experiment [1]: | |
Cell lines | A549, DU145, and MIA PaCa-2 cells |
Preparation Method | Cells were treated with 50µM of matrine for several time intervals(0, 6,12, 24h). mRNA level was measured by RT-PCR, used GAPDH as a loading control. Then expression levels of CXCR4, MMP-2, MMP-9 was compared on each cell lines. |
Reaction Conditions | 50µM; 0, 6,12, 24h |
Applications | Matrine decreased the CXCR4 expression as well as MMP-2 and MMP-9 levels in A549, DU145, and MIA PaCa-2 cells. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Intraperitoneal injection of streptozotocin (65mg/kg) was employed to induce diabetes in rats. Prior to the induction of diabetes, rats were administered with matrine orally at a dose of 300 mg/kg per day for 10 days. |
Dosage form | 300mg/kg/day; p.o. |
Applications | Matrine attenuates left ventricular functions impairment in experimental rat model of Diabetic cardiomyopathy (DbCM), recovers cardiac compliance loss, inhibits cardiac fibrosis induced by the activation of the TGF-β1/Smad signaling pathway. |
References: [1] Jung Y Y, Um J Y, Narula A S, et al. Identification of matrine as a novel regulator of the CXCR4 signaling axis in tumor cells[J]. International Journal of Molecular Sciences, 2020, 21(13): 4731. [2] Zhang Y, Cui L, Guan G, et al. Matrine suppresses cardiac fibrosis by inhibiting the TGF‑β/Smad pathway in experimental diabetic cardiomyopathy[J]. Molecular Medicine Reports, 2018, 17(1): 1775-1781. | |
| Cas No. | 519-02-8 | SDF | |
| Überlieferungen | NSC 146051, NSC 318810 | ||
| Chemical Name | (41S,7aS,13aR,13bR)-dodecahydro-1H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10(41H)-one | ||
| Canonical SMILES | O=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CCC1 | ||
| Formula | C15H24N2O | M.Wt | 248.36 |
| Löslichkeit | ≥ 12.4 mg/mL in DMSO, ≥ 47.2 mg/mL in EtOH, ≥ 50.3 mg/mL in Water with ultrasonic and warming | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.0264 mL | 20.1321 mL | 40.2641 mL |
| 5 mM | 805.3 μL | 4.0264 mL | 8.0528 mL |
| 10 mM | 402.6 μL | 2.0132 mL | 4.0264 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)